Variable | Categories | Total | NHW | AA | HW | P 1 | ||||
---|---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | |||
Total | Â | 366 | 100 | 58 | 16 | 73 | 20 | 235 | 64 | Â |
Age (years) | < 50 | 95 | 26 | 18 | 31 | 19 | 26 | 58 | 25 | 0.613 |
≥ 50 | 271 | 74 | 40 | 69 | 54 | 74 | 177 | 75 |  | |
Mean (SD) | 56.0 (9.1) | 55.6 (9.1) | 54.9 (9.2) | 56.5 (9.1) | Â | |||||
BMI (kg/m2) | < 25 | 96 | 26 | 29 | 50 | 12 | 16 | 55 | 23 | < 0.0001 |
25–29.9 | 124 | 34 | 16 | 28 | 17 | 23 | 91 | 39 |  | |
≥ 30 | 146 | 40 | 13 | 22 | 44 | 60 | 89 | 38 |  | |
Mean (SD) | 29.3 (6.4) | 26.6 (6.3) | 32.6 (8.4) | 28.9 (5.2) | Â | |||||
Smoking status | Never | 240 | 66 | 37 | 64 | 51 | 70 | 152 | 64 | 0.490 |
Former | 107 | 29 | 20 | 34 | 17 | 23 | 70 | 30 | Â | |
Current | 19 | 5 | 1 | 2 | 5 | 7 | 13 | 6 | Â | |
Sum of 12 comorbid conditions2 | 0 | 147 | 40 | 28 | 48 | 19 | 26 | 100 | 43 | 0.119 |
1 | 137 | 37 | 20 | 34 | 32 | 44 | 85 | 36 | Â | |
2 | 60 | 16 | 7 | 12 | 18 | 25 | 35 | 15 | Â | |
≥ 3 | 22 | 6 | 3 | 5 | 4 | 5 | 15 | 6 |  | |
Tumor stage | 0 | 74 | 20 | 7 | 12 | 14 | 19 | 53 | 23 | 0.003 |
IA-B | 180 | 49 | 37 | 64 | 28 | 38 | 115 | 49 | Â | |
IIA-B | 90 | 25 | 13 | 22 | 29 | 40 | 48 | 20 | Â | |
IIIA-C | 22 | 6 | 1 | 2 | 2 | 3 | 19 | 8 | Â | |
ER | Positive | 279 | 76 | 43 | 74 | 49 | 67 | 187 | 80 | 0.072 |
Negative | 86 | 23 | 15 | 26 | 24 | 33 | 47 | 20 | Â | |
PR | Positive | 243 | 66 | 36 | 62 | 44 | 60 | 163 | 69 | 0.243 |
Negative | 122 | 33 | 22 | 38 | 29 | 40 | 71 | 30 | Â | |
HER2 | Positive | 31 | 8 | 4 | 7 | 6 | 8 | 21 | 9 | 0.730 |
Negative | 275 | 75 | 50 | 86 | 56 | 77 | 169 | 72 | Â | |
Triple negative | No | 294 | 80 | 47 | 81 | 52 | 71 | 195 | 83 | 0.005 |
Yes | 54 | 15 | 8 | 14 | 20 | 27 | 26 | 11 | Â | |
Axillary surgery | None/SLNB | 248 | 68 | 39 | 67 | 54 | 74 | 155 | 66 | 0.439 |
ALND | 118 | 32 | 19 | 33 | 19 | 26 | 80 | 34 | Â | |
Chemotherapy | No | 195 | 53 | 31 | 53 | 39 | 53 | 125 | 53 | 0.999 |
Yes | 171 | 47 | 27 | 47 | 34 | 47 | 110 | 47 | Â | |
Hormone therapy/initiation time | None/after RT | 178 | 49 | 37 | 64 | 41 | 56 | 100 | 43 | 0.015 |
Aromatase inhibitor before RT | 98 | 27 | 9 | 16 | 14 | 19 | 75 | 32 | Â | |
Aromatase inhibitor during RT | 14 | 4 | 3 | 5 | 2 | 3 | 9 | 4 | Â | |
Tamoxifen before RT | 64 | 17 | 6 | 10 | 12 | 16 | 46 | 20 | Â | |
Tamoxifen during RT | 12 | 3 | 3 | 5 | 4 | 5 | 5 | 2 | Â | |
RT fractionation | Conventional | 306 | 84 | 45 | 78 | 64 | 88 | 197 | 84 | 0.298 |
Hypo | 60 | 16 | 13 | 22 | 9 | 12 | 38 | 16 | Â | |
Total RT dose (Gy) | < 60 | 107 | 29 | 21 | 36 | 18 | 25 | 68 | 29 | 0.348 |
≥ 60 | 259 | 71 | 37 | 64 | 55 | 75 | 167 | 71 |  | |
Mean (SD) | 58.2 (4.8) | 58.4 (4.6) | 58.7 (4.9) | 58.0 (4.8) | Â | |||||
Boost | Yes | 331 | 90 | 56 | 97 | 65 | 89 | 210 | 89 | 0.225 |
No | 35 | 10 | 2 | 3 | 8 | 11 | 25 | 11 | Â | |
Breast volume (cc) | < 892.1 (median) | 183 | 50 | 38 | 66 | 20 | 27 | 125 | 53 | < 0.001 |
≥ 892.1 (median) | 179 | 49 | 20 | 34 | 52 | 71 | 107 | 46 |  | |
Mean (SD) | 996 (532) | 799 (464) | 1254 (645) | 965 (479) | Â | |||||
Pre-RT pain | Mean (SD) | 1.7 (2.1) | 1.0 (1.3) | 2.0 (2.5) | 1.8 (2.1) | 0.023 | ||||
Post-RT pain | Mean (SD) | 2.8 (2.5) | 1.9 (1.7) | 3.2 (2.6) | 2.8 (2.6) | 0.013 |